Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer

BACKGROUND: Type II cancers account for 10% of endometrial cancers but 50% of recurrence. Response rates to chemotherapy at recurrence are poor and better prognostic markers are needed to guide therapy. CD151 is a small transmembrane protein that regulates cell migration and facilitates cancer metas...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Voss, M A, Gordon, N, Maloney, S, Ganesan, R, Ludeman, L, McCarthy, K, Gornall, R, Schaller, G, Wei, W, Berditchevski, F, Sundar, S
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2011
Teme:
Molecular Diagnostics
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3101917/
https://ncbi.nlm.nih.gov/pubmed/21505452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.80
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items